InMed Pharmaceuticals Inc (INM)

[NetworkNewsWire]

IMLFF Announces Inclusion in CSE25 Index

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has been included in the CSE25 Index after qualifying as one of the 25 largest companies in the CSE Composite Index. Per the update, the CSE25 Index is a subgroup of the CSE Composite Index, which was launched in 2015 and currently includes nearly half of the exchange’s listed companies and over 75 percent of the trading activity on the Canadian Securities Exchange. The CSE25 Index includes the top 25 securities contained within the CSE Composite Index based on market capitalization. According to the exchange, CSE25 companies account for more than 50 percent of the weighting of the larger CSE Composite Index, meaning that the 25 included stocks typically attract “considerable trading volume.”

To view the full press release, visit http://nnw.fm/EQn42

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.